Suppr超能文献

**阿联酋第一次炎症性肠病诊断和管理共识:2020 年德尔菲共识**

First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

机构信息

Gastroenterology and Endoscopy Department, Ibrahim Bin Hamad Obaid Allah Hospital, Ministry of Health and Prevention, Ras Al Khaiman, United Arab Emirates.

Department of Gastroenterology, Sheikh Shakbout Medical City, Abu Dhabi, United Arab Emirates.

出版信息

World J Gastroenterol. 2020 Nov 21;26(43):6710-6769. doi: 10.3748/wjg.v26.i43.6710.

Abstract

Ulcerative colitis and Crohn's disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract. The incidence and prevalence are on the rise worldwide, and the heterogeneity between patients and within individuals over time is striking. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients. This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations. Comprehensive up-to-date guidance is provided regarding diagnosis, evaluation of disease severity, appropriate and timely use of different investigations, choice of appropriate therapy for induction and remission phase according to disease severity, and management of main complications.

摘要

溃疡性结肠炎和克罗恩病是炎症性肠病的主要实体,其特征为胃肠道慢性缓解性炎症。该病在全球范围内的发病率和患病率呈上升趋势,且患者之间以及个体随时间的异质性非常显著。随着我们对其发病机制的理解不断深入,以及治疗选择的空前增加,临床医生在治疗患者时,已逐渐采用基于循证医学的干预措施。本指南是在阿联酋胃肠病学和肝病学会的支持下制定的,其制定过程是对相关文献进行系统回顾,并通过德尔菲共识程序提供了基于证据和专家意见的建议。本指南就疾病的诊断、严重程度的评估、不同检查的合理适时应用、根据疾病严重程度选择适当的诱导缓解期治疗方案以及主要并发症的管理等方面提供了全面且最新的指导建议。

相似文献

1
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.
World J Gastroenterol. 2020 Nov 21;26(43):6710-6769. doi: 10.3748/wjg.v26.i43.6710.
2
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
3
Inflammatory Bowel Disease: A Concise Review.
S D Med. 2023 Sep;76(9):416-423.
6
[Inflammatory bowel disease: an overview].
Med Monatsschr Pharm. 2013 Nov;36(11):402-8; quiz 409.
7
AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.
Gastroenterology. 2024 Mar;166(3):521-532. doi: 10.1053/j.gastro.2023.11.303. Epub 2024 Jan 23.
8
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
10
Management issues in women with inflammatory bowel disease.
J Am Osteopath Assoc. 2001 Dec;101(12 Suppl Pt 2):S17-23.

引用本文的文献

2
Screening and evaluation of key technologies for non-bioartificial liver care: an empirical study.
Front Med (Lausanne). 2025 Jan 7;11:1459428. doi: 10.3389/fmed.2024.1459428. eCollection 2024.
5
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.
Therap Adv Gastroenterol. 2024 Feb 24;17:17562848241230902. doi: 10.1177/17562848241230902. eCollection 2024.
7
Predicting Mucosal Healing in Crohn's Disease: A Nomogram Model Developed from a Retrospective Cohort.
J Inflamm Res. 2022 Sep 23;15:5515-5525. doi: 10.2147/JIR.S378304. eCollection 2022.
9
A review of the therapeutic management of Crohn's disease.
Therap Adv Gastroenterol. 2022 Feb 17;15:17562848221078456. doi: 10.1177/17562848221078456. eCollection 2022.
10
Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates.
Therap Adv Gastroenterol. 2021 Dec 22;14:17562848211065329. doi: 10.1177/17562848211065329. eCollection 2021.

本文引用的文献

1
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms.
Drugs Context. 2020 Mar 2;9. doi: 10.7573/dic.2019-10-2. eCollection 2020.
2
Ulcerative Colitis and Cytomegalovirus Infection: From A to Z.
J Crohns Colitis. 2020 Sep 7;14(8):1162-1171. doi: 10.1093/ecco-jcc/jjaa036.
3
Men With Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer.
Am J Gastroenterol. 2020 Apr;115(4):526-534. doi: 10.14309/ajg.0000000000000515.
4
How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?
Clin Gastroenterol Hepatol. 2020 May;18(6):1300-1308. doi: 10.1016/j.cgh.2019.12.020. Epub 2019 Dec 27.
5
A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos).
Gastrointest Endosc. 2020 Apr;91(4):733-745. doi: 10.1016/j.gie.2019.11.032. Epub 2019 Nov 29.
6
How to manage chronic diarrhoea in the elderly?
Frontline Gastroenterol. 2019 Oct;10(4):427-433. doi: 10.1136/flgastro-2018-101097. Epub 2019 Apr 29.
7
Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients.
Aliment Pharmacol Ther. 2019 Nov;50(9):1009-1018. doi: 10.1111/apt.15497. Epub 2019 Oct 8.
8
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
9
Biologics beyond Anti-TNF Agents for Ulcerative Colitis - Efficacy, Safety, and Cost?
N Engl J Med. 2019 Sep 26;381(13):1279-1281. doi: 10.1056/NEJMe1910742.
10
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验